Do It Yourself: Advantages Of Internal Gene Therapy Manufacturing

The number of gene therapies in development continues to rise, as trial sponsors widen the scope of addressable conditions, beyond ultra-rare diseases. Will manufacturing capacity – and payer budgets – be able to keep up?

genetic medicine with Manufacturing Focus logo
• Source: Shutterstock

If deal activity, capital investment and quantity of active clinical trials are any indication, the gene therapy sector will continue its growth spurt in 2021. At the end of the third quarter of 2020, 97 gene therapies had entered Phase III trials, and gene therapy financing amounts had increased by 114% year-to-date, reaching $12bn, according to data from the Alliance for Regenerative Medicine (ARM).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing Focus

More from In Vivo

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Rising Leaders 2025: Christina Ziegenberg On Keeping Medtechs Competitive And MDR Compliant

 
• By 

Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.

Financing Quarterly Statistics, Q1 2025

 
• By 

During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.